Targeting Protein Tyrosine Phosphatases for Anticancer Drug Discovery

Title: Targeting Protein Tyrosine Phosphatases for Anticancer Drug Discovery

Volume: 16 Issue: 16

Author(s): Latanya M. Scott, Harshani R. Lawrence, Said M. Sebti, Nicholas J. Lawrence and Jie Wu

Affiliation:

Keywords: Protein tyrosine phosphatase inhibitor, Shp2, PTP1B, Cdc14, PRL-3, LMW-PTP, Cdc25, eya

Abstract: Protein tyrosine phosphatases (PTPs) are a diverse family of enzymes encoded by 107 genes in the human genome. Together with protein tyrosine kinases (PTKs), PTPs regulate various cellular activities essential for the initiation and maintenance of malignant phenotypes. While PTK inhibitors are now used routinely for cancer treatment, the PTP inhibitor development field is still in the discovery phase. In this article, the suitability of targeting PTPs for novel anticancer drug discovery is discussed. Examples are presented for PTPs that have been targeted for anticancer drug discovery as well as potential new PTP targets for novel anticancer drug discovery.

Cite this article as:

M. Scott Latanya, R. Lawrence Harshani, M. Sebti Said, J. Lawrence Nicholas and Wu Jie, Targeting Protein Tyrosine Phosphatases for Anticancer Drug Discovery, Current Pharmaceutical Design 2010; 16 (16) . https://dx.doi.org/10.2174/138161210791209027